Many analysts have voiced fears that the U.S. stock markets march higher is overdone.
One chart watcher, on the other hand, is suggesting the opposite.
The breakout could be just getting started, wrote Jonathan Krinsky, chief market technician at MKM Partners, in a note dated Sunday.
This view comes after Krinsky looked not at the S&P 500
or the Dows
30 blue chips, but rather at the Value Line Geometric Index
, which consists of about 1,675 U.S. stocks.
Best Blue Chip Stocks For 2018: Sarepta Therapeutics, Inc.(SRPT)
- [By Lisa Levin]
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares were also up, gaining 16 percent to $47.52 following the announcement of positive results in its study for the treatment of Duchenne Muscular Dystrophy.
- [By Ben Levisohn]
Skorney’s namesVertex Pharmaceuticals (VRTX),Sarepta Therapeutics (SRPT), and Curis (CRIS) his top biotech picks for 2017, while Ulz chosesBioMarin Pharmaceutical (BMRN) andParatek Pharmaceuticals (PRTK).
- [By Chris Lange]
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw its shares make a handy gain on Tuesday following its presentation at the JPMorgan Healthcare Conference. The companys Duchenne muscular dystrophy (DMD) drug, Exondys 51, generated better than expected sales clocking in at $5.4 million in the fourth quarter. Previously, this DMD treatment was approved by the FDA just as recently as September 2016.
- [By Johanna Bennett]
Will healthinsurers pay for Sarepta Therapeutics (SRPT) Exondys 51?
Thats a question that several analysts have weighed on today. It appears that payors are still actively evaluating and reevaluating coverage of the Duchenne muscular dystrophy drug Exondys 51.
Approved by the FDA in September, the drug has met with widespread pushback from insurers like Anthem (ANTM), Humana (HUM) and UnitedHealth Group (UNH) amid concerns about its efficacy. So while Sareptas share price has more than doubled over the past 12 months, it has made a sharp retreat, falling 50% to just under $32 a share since hitting a record high $63.73 a share in late September.
But Cowen analyst Ritu Baral says the tide maybe turning, arguing that coverage denials wont be permanent.
As SRPT management and our Neuromuscular Disease panelist indicated to us at our recent Healthcare Conference, payor discussions are continuing regarding Exondys 51 with manageable, increasingly positive feedback. Of the major plans we have seen coverage policies released for, only Anthem (including Blue Cross Blue Shield) had previously denied coverage of Exondys, though patients could petition for coverage via a standard appeal process (see further below). Based on their February Specialty Pharmacy Medical Management Prior Authorization Drug List, it appears Anthem will add Exondys 51 to its prior auth list as of 5/1. We think this is encouraging and indicative of the evolving payor landscape surrounding Exondys 51 and more broadly, DMD. Anthem’s pick-up, together with those such as United, which started coverage on 2/1, support the idea of accelerating new patient starts, suggested by SRPT last week at our Healthcare Conference.
…But Coverage Denials Persist (For Now), Especially Among Non-Ambulatory Patients. While we think the overwhelming majority of amenable patients will eventually be covered for Exondys 51, we do note several social media anecdote
- [By Dan Caplinger]
Yet some stocks didn’t participate in the rally, instead contending with negative news of their own. Zoe’s Kitchen (NYSE:ZOES), GOL Lineas Aereas Inteligentes (NYSE:GOL), and Sarepta Therapeutics (NASDAQ:SRPT) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.
Best Blue Chip Stocks For 2018: Alliance Data Systems Corporation(ADS)
- [By Chris Lange]
The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Thursday was Alliance Data Systems Corp. (NYSE: ADS) which jumped 8.3% to $260.56. The stocks 52-week range is $185.02 to $263.40. Volume was roughly 1.2 million which is above the daily average of around 606,000 shares.
- [By Teresa Rivas]
Alliance Data Systems (ADS) was the worst performer in the S&P 500 Tuesday.
ADS shares fell $9.32, or 3.8%, to $238.32, compared to the S&P 500, which fell 3.38 points, or 0.14%, to 2353.78.
The shares were hurt by a bearish note from Oppenheimer: Analysts Ben Chittenden and Dominick Gabriele initiated coverage of the stock with an Underperform rating and a $185 price target.
Details from the note:
Long investors seem generally to believe that the profitability of ADS’s capital-light/data-driven/tech-based businesses (Epsilon/LoyaltyOne) will turn relatively soon and that EPS will be driven by more than just the card business. The logical conclusion is the multiple should be FinTech-based. We think it’s just as easy to make the case that, while ADS had a first-mover advantage on data-driven, SKU-level analytics, competitive advantage is diminishing and the profitability of these businesses will likely take longer to turn (and likely not return to historical levels). Thus, earnings will continue to be driven by the balance sheet-intensive card business (our ’18E EPS is 6% below consensus) and should be valued as such, we think.
Advanced Micro Devices(AMD) was the worst performer in the S&P 500 yesterday.
- [By Chris Lange]
The S&P 500 stock posting the largest daily percentage loss ahead of the close Tuesday was Alliance Data Systems Corp. (NYSE: ADS) which traded down 3.9% at $238.00. The stocks 52-week range is $185.02 to $254.94. Volume was 1.6 million versus the daily average of 577,000 shares.
- [By Ben Levisohn]
Alliance Data Systems (ADS) soared to the top of the S&P 500 today after beating the Street’s earnings and revenue expectations.
Alliance Data Systemsgained 8.3% to $260.62, while the S&P 500 rose 0.8% to 2,355.84.
Evercore ISI’s David Togut and team argue that Alliance Data Systems is “checking the right boxes.” They explain:
ADS’ 1Q/17 earnings reinforced our conviction that net charge offs will stabilize at the end of this year, driving accelerating earnings growth in 2018. Card Services surpassed our revenue and EBITDA forecasts fueled by an 80 basis point increase in gross card yield thanks to rising interest rates. Epsilon’s revenue growth accelerated to 7% from a 1% decline in 4Q/16 driven by double digit growth in Automotive, Agency and digital CRM plus an easy comparison. LoyaltyOne revenue and EBITDA fell below our estimates given soft results from AIR MILES, which is adjusting its value proposition after the Ontario Legislature last December eliminated the expiration date on AIR MILES. Overall, ADS remains on track to generate double-digit adjusted EBITDA and EPS gains in 2017, and in 2018 to accelerate EPS growth to the mid-teens given slowing headwinds from delinquencies plus operating leverage from stabilizing net charge-off rates.
Alliance Data Systems’ market capitalization rose to $14.6 billion today from $13.5 billion yesterday.
Best Blue Chip Stocks For 2018: TRC Companies Inc.(TRR)
- [By Lisa Levin]
Shares of TRC Companies, Inc. (NYSE: TRR) got a boost, shooting up 16 percent to $7.53. TRC posted Q4 earnings of $0.20 per share on revenue of $132.3 million.